Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- BDB-001
- DrugBank Accession Number
- DB16480
- Background
BDB-001, was under investigation in multiple clinical trials to evaluate its safety, tolerability, and efficacy across various conditions. In NCT05075304 and NCT04449588, BDB-001 was studied in mild to severe COVID-19 patients. It was also explored for solid tumors in NCT03486301, NCT04196530, and NCT04819373, either as monotherapy or combined with Pembrolizumab or Atezolizumab, and in NCT03915678 with Atezolizumab and immunogenic radiotherapy. Additionally, NCT05197842 investigated its use in ANCA-associated vasculitis, and NCT05103423 and NCT05093855 focused on moderate to severe Hidradenitis Suppurativa.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- BDB 001
- BDB001
- External IDs
- BDB-001
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
BDB-001 is an anti-C5RA1 monoclonal antibody activating the toll-like receptor. It has potential antineoplastic and immunostimulating activities.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Chen G, Li N, Dai X, Tu S, Shen Z, Wu K, Jin T, Wu J, Peng C, Sheng G, Zhu M, Tang L, Li L: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults. Infect Dis Ther. 2023 Feb;12(2):663-675. doi: 10.1007/s40121-023-00759-4. Epub 2023 Jan 25. [Article]
- External Link [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Hidradenitis Suppurativa (HS) 1 somestatus stop reason just information to hide 2 Completed Treatment Solid Tumors 1 somestatus stop reason just information to hide 2 Recruiting Treatment Adult Solid Tumor / Bladder Cancer / Melanoma / Non-Small Cell Lung Cancer (NSCLC) / Pancreatic Cancer / Triple-Negative Breast Cancer / Virus-associated Tumors 1 somestatus stop reason just information to hide 2, 3 Terminated Treatment Coronavirus Disease 2019 (COVID‑19) / COVID-19 Pneumonia 1 somestatus stop reason just information to hide 1 Active Not Recruiting Treatment Solid Tumors 2 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at January 21, 2021 01:47 / Updated at July 20, 2024 09:09